As the first proteasome inhibitor, Vanco inhibits the degradation of several important regulatory proteins and induces apoptosis; it also affects the microenvironment of tumor cell growth and inhibits the growth and survival of tumor cells in the microenvironment, and is active in the treatment of various tumors. Since its inception, Vanco has been awarded the Oncology Compound of the Year Award in 2004 and the Prix Galien Award in 2006, the latter of which is known as the “Nobel Prize of the pharmaceutical industry”. In 2003, the U.S. Food and Drug Administration (FDA) approved VANCOUVER for the clinical treatment of multiple myeloma (MM), and in 2005, the FDA and the European Medicines Review Agency approved VANCOUVER for the treatment of MM after the first relapse. Currently, the 2010 NCCN (National Comprehensive Cancer Network) guidelines recommend VANCOUVER as the drug of choice for the treatment of MM. The efficacy of VANCOUVER in treating multiple myeloma is remarkable. The combination of Vancor with various chemotherapeutic agents, including dexamethasone, adriamycin, thalidomide and malafarin, has a synergistic effect. The overall remission rate (CR+PR) of Vancor (V) in combination with dexamethasone, malafarin (M), prednisone (P), thalidomide, and doxorubicin (Adriamycin) in patients with primary treatment of multiple myeloma is 50% to 80%. The results of an international multicenter study comparing MPV with MP showed that the MPV regimen was highly effective and could become the standard of care for elderly patients with myeloma. The combination regimen of VANCO is also used in relapsed refractory multiple myeloma, and the above combination regimens have achieved good efficacy in the treatment of relapsed refractory myeloma.